申请人:——
公开号:US20030018035A1
公开(公告)日:2003-01-23
Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF
1
receptors, including human CRF
1
receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF
1
receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
提供了芳基吡嗪化合物,包括可以与CRF1受体结合并具有高亲和力和高选择性的芳基吡嗪,包括人类CRF1受体。因此,该发明涉及用于治疗与CRF1受体相关的疾病和疾病的方法,包括与中枢神经系统相关的疾病和疾病,特别是情感障碍和疾病以及急性和慢性神经系统疾病。